Fig 1.
Results of the Literature Search.
CCTR = Cochrane controlled trials register; EU = European Union; FDA = Food and Drug Administration; HbA1c = hemoglobin A1c.
Fig 2.
Network Diagram of Randomized Controlled Trials Evaluating Antidiabetic Therapies in Addition to Optimized Metformin in Type 2 Diabetes.
All agents are in combination with optimized metformin and include oral and subcutaneous agents and long-acting, once daily basal insulins. Lines represent the presence of direct comparison trial(s). The width of the line is proportional to the number of trials with direct comparisons. ACA, acarbose; ALO, alogliptin; ALO/PIO, alogliptin/pioglitazone; CANA, canagliflozin; COL, colesevelam; DAPA, dapagliflozin; EMPA, empagliflozin; EMPA/LINA, empagliflozin/linagliptin; EXEN, exenatide; GLAR, insulin glargine; GLIB, glibenclamide; GLIC, gliclazide; GLIM, glimeperide; GLIP, glipizide; LINA, linagliptin; LIRA, liraglutide; LIX, lixisenatide; MIG, miglitol; NAT, nateglinide; PIO, pioglitizone; PLC, placebo; REP, repaglinide; ROSI, rosiglitizone; SAX, saxagliptin; SITA, sitagliptin; VILDA, vildagliptin
Table 1.
Outcomes Reported In Randomized Controlled Trials Evaluating Antidiabetic Therapies Added to Metformin in Adult Patients With Type 2 Diabetes.
Table 2.
Results of Network Meta-Analysis and Traditional Pair-Wise Meta-Analysis Comparing Antidiabetic Therapies’ Effect on Change in HbA1c, Body Weight and Systolic Blood pressure.
Table 3.
Results of Network Meta-Analysis and Traditional Meta-Analysis Comparing Antidiabetic Therapies’ Effect on Confirmed Hypoglycemia, Urinary and Genital Tract Infection.